Brokerages Set Reata Pharmaceuticals, Inc. (NASDAQ:RETA) PT at $115.14

Reata Pharmaceuticals, Inc. (NASDAQ:RETAGet Rating) has earned an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $115.14.

Several analysts have weighed in on RETA shares. StockNews.com started coverage on shares of Reata Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. The Goldman Sachs Group raised shares of Reata Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $34.00 to $91.00 in a research note on Thursday, March 24th.

NASDAQ:RETA traded down $2.39 during midday trading on Monday, hitting $34.11. The company had a trading volume of 329,080 shares, compared to its average volume of 859,566. Reata Pharmaceuticals has a 52-week low of $22.71 and a 52-week high of $153.41. The stock’s fifty day moving average price is $31.99 and its 200-day moving average price is $53.32. The company has a market capitalization of $1.24 billion, a PE ratio of -4.17 and a beta of 1.14.

Reata Pharmaceuticals (NASDAQ:RETAGet Rating) last announced its earnings results on Monday, February 28th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.31) by ($0.04). Reata Pharmaceuticals had a negative return on equity of 105.72% and a negative net margin of 2,588.22%. During the same quarter in the previous year, the business earned ($1.90) earnings per share. On average, sell-side analysts predict that Reata Pharmaceuticals will post -9.29 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its holdings in Reata Pharmaceuticals by 16.7% in the third quarter. Russell Investments Group Ltd. now owns 41,215 shares of the company’s stock worth $4,145,000 after buying an additional 5,898 shares during the period. Transcend Wealth Collective LLC bought a new position in shares of Reata Pharmaceuticals during the third quarter valued at approximately $485,000. MADDEN SECURITIES Corp increased its position in shares of Reata Pharmaceuticals by 18.7% during the fourth quarter. MADDEN SECURITIES Corp now owns 39,312 shares of the company’s stock valued at $1,037,000 after acquiring an additional 6,185 shares in the last quarter. Invesco Ltd. increased its position in shares of Reata Pharmaceuticals by 22.4% during the third quarter. Invesco Ltd. now owns 3,438,804 shares of the company’s stock valued at $345,978,000 after acquiring an additional 629,088 shares in the last quarter. Finally, Credit Suisse AG increased its position in shares of Reata Pharmaceuticals by 7.9% during the third quarter. Credit Suisse AG now owns 27,725 shares of the company’s stock valued at $2,789,000 after acquiring an additional 2,026 shares in the last quarter. Institutional investors and hedge funds own 72.49% of the company’s stock.

About Reata Pharmaceuticals (Get Rating)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Featured Articles

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.